Table 3. Cell proliferation assessed by CCK-8 assay after miR-196b and siRNA transfection.
n | ±s | |
miR-196b inhibitor | 3 | 3.674±0.080* |
miR-196b inhibitorcontrol | 3 | 1.690±0.035 |
miR-196b mock | 3 | 1.703±0.018 |
cells with over-expressedmiRNA-196b | 3 | 1.716±0.079 |
K562 | 3 | 2.611±0.103 |
F | 336.464 | (welch) |
P | <0.001 | |
BCR-ABL1 siRNA | 3 | 1.821±0.063** |
HOXA9 siRNA | 3 | 1.939±0.079# |
NC siRNA | 3 | 2.717±0.126 |
mock siRNA | 3 | 2.654±0.075 |
K562 | 3 | 2.675±0.129 |
cells with over-expressedmiRNA-196b | 3 | 1.676±0.060 |
F | 69.425 | (welch) |
P | <0.001 |
vs. miR-196b inhibitor control, P = 0.001; * vs. miR-196b mock, P = 0.003; * vs. cells with over-expressed miRNA-196b, P<0.001; * vs. K562, P = 0.002; cells with over-expressed miRNA-196b vs. K562, P = 0.004 (missing case, pairwise comparisons). ** vs. HOXA9 siRNA, P = 0.851; ** vs. K562, P = 0.032; **vs. cells with over-expressed miRNA-196b, P = 0.495; # vs. K562, P = 0.034; # vs. cells with over-expressed miRNA-196b, P = 0.166 (missing case, pairwise comparisons).